A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancer Letters Année : 2014

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.

Résumé

Breast cancer (BC) displays a high heterogeneity from histology to prognosis, metastatic evolution and treatment responses. We report here a (1)H NMR-based metabolic phenotyping study aiming at identifying coordinated metabolic serum changes associated with advanced metastatic breast cancer (MBC) in comparison to the localized early disease (EBC). A model discriminating EBC and MBC patients is obtained (n=85: 46 EBC and 39 MBC), and validated with an independent cohort (n=112: 61 EBC and 51 MBC; 89.8% sensitivity, 79.3% specificity). We identify 9 statistically significant metabolites involved in this discrimination: histidine, acetoacetate, glycerol, pyruvate, glycoproteins (N-acetyl), mannose, glutamate and phenylalanine. This work illustrates the strong potential of NMR metabolic phenotyping for the diagnosis, prognosis, and management of cancer patients.
Fichier non déposé

Dates et versions

hal-00977546 , version 1 (11-04-2014)

Identifiants

Citer

Elodie Jobard, Clément Pontoizeau, Benjamin J. Blaise, Thomas Bachelot, Bénédicte Elena-Herrmann, et al.. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.. Cancer Letters, 2014, 343 (1), pp.33-41. ⟨10.1016/j.canlet.2013.09.011⟩. ⟨hal-00977546⟩
85 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More